Targets › BDKRB2
1 program from 1 company in 7 trials: 3 Phase 4, 2 Phase 3, 2 Phase 2; Neurology, Cardiovascular, Gastroenterology; next expected readout Nov 2026.
Receptor for bradykinin. It is associated with G proteins that activate a phosphatidylinositol-calcium second messenger system. (UniProt, P30411)
Open in Phaseline: the race on BDKRB2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Vanderbilt University Medical Center | [18F]MH.MZ Bacterial penicillin-binding protein inhibitor | HTR2A, UNKNOWN, BDKRB2, Ion channels | Phase 4 | Neurodegenerative Diseases; Osteoarthritis, Knee; Pain; Intradialytic Hypotension … | Nov 2026 |
Neurodegenerative Diseases (1) Osteoarthritis, Knee (1) Pain (1) Intradialytic Hypotension (1) End Stage Renal Disease (1) Microtia (1) Acute Uncomplicated Diverticulitis (1)
small molecule (1)
Vanderbilt University Medical Center (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.